Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021
Multiple myeloma (MM) is a deadly bone marrow cancer. In recent years, the treatment landscape for this disease has improved considerably. However, most patients still relapse and the need for new and better therapeutic options endures. Encouraging news about several approaches were reported at the American Society of Hematology (ASH) in December. Results from...